Anebulo Pharmaceuticals, Inc. Annual report pursuant to Section 13 and 15(d)

Accrued Expenses

12 Months Ended

Jun. 30, 2023

Note 3. Accrued Expenses

Accrued expenses consisted of the following:

Schedule of Accrued Expenses

	2023		2022
	June 30,
	2023		2022
Accrued research and development	$	344,135	$	105,980
Accrued payroll related expenses		190,121		25,723
Total accrued expenses	$	534,256	$	131,703